RCS - Ripple Therapeutics - Ripple Therapeutics Announces Collaboration

AbbvieAnnouncement

17/09/2024 14:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240917:nRSQ4343Ea&default-theme=true

RNS Number : 4343E  Ripple Therapeutics  17 September 2024

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement
with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

- Collaboration to leverage AbbVie's eye care expertise and Ripple's
innovative drug delivery platform to develop next-generation sustained release
drug delivery implants for the treatment of glaucoma

TORONTO, ON / ACCESSWIRE / September 17, 2024 / Ripple Therapeutics today
announced a collaboration and option-to-license agreement with AbbVie to
develop RTC-620, a next generation, fully biodegradable, sustained release
drug delivery intracameral implant with repeat dosing capabilities to reduce
intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or
ocular hypertension (OHT). This collaboration leverages AbbVie's expertise in
eye care and Ripple's innovative drug delivery platform.

Ripple's patented technology platform is based on a discovery that drugs can
be engineered into controlled release pharmaceuticals without the use of
polymers or excipients. These proprietary prodrugs undergo surface erosion to
give zero order release kinetics and are highly customizable to tailor both
drug dose and duration. Because there are no polymers or excipients, once the
drug is gone, the implant is gone with no pro-inflammatory degradation
products, which supports repeat dosing.

"We're pleased to partner with AbbVie, a worldwide leader in ophthalmic
therapeutics," said Tom Reeves, President and Chief Executive Officer, Ripple
Therapeutics. "By combining our drug delivery platform with AbbVie's research,
clinical, regulatory and commercial capabilities, we hope to deliver a
meaningful impact on the lives of people living with glaucoma."

Millions of people are living with glaucoma, one of the leading causes of
vision loss. New treatment options are needed to help patients challenged with
topical drops or who are at risk for vision loss and looking for alternative
treatment options.

"At AbbVie, we strive to find innovative solutions to build our portfolio of
vision-preserving therapies," said Michael Robinson, M.D., Vice President and
Therapeutic Area Head, Ophthalmology, AbbVie. "We are excited to partner with
Ripple to further advance the development of RTC-620."

Under terms of the agreement, Ripple will lead preclinical development of
RTC-620. Upon exercise of the option, AbbVie will lead the clinical and
commercialization activities. Ripple will receive an upfront payment of $21.8
million from AbbVie and is eligible to receive up to $290 million in aggregate
option fees and milestones, as well as tiered royalties on net sales.

About Ripple Therapeutics

Ripple Therapeutics Corporation is a privately held clinical stage company
focused on improving ophthalmic therapeutics with controllable sustained
delivery implants without the use of polymers or excipients. Our novel
therapeutics provide better outcomes for patients, easier management of care
for physicians and lower cost for payors. www.rippletherapeutics.com
(https://pr.report/2nq1)

Piper Sandler acted as the exclusive financial advisor to Ripple.

For further information:

Media: Julie Fotheringham, jfotheringham@rippletherapeutics.com, 416-951-7988

SOURCE: Ripple Therapeutics

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQKABNNBKBPCD